We are live on ! Find out more
TVTX icon

Travere Therapeutics
TVTX

124 hedge funds and large institutions have $643M invested in Travere Therapeutics in 2020 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $611M → $643M (+$31.6M)

1.98% more ownership

Funds ownership: 100.14% → 102.12% (+2%)

5% less funds holding

Funds holding: 131 → 124 (-7)

23% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 26

35% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 49

63% less call options, than puts

Call options by funds: $1.67M | Put options by funds: $4.51M

Holders
124
Holders Change
-7
Holders Change %
-5.34%
% of All Funds
2.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
32
Reduced
49
Closed
26
Calls
$1.67M
Puts
$4.51M
Net Calls
-$2.85M
Net Calls Change
-$958K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$14.5M
2
Goldman Sachs
Goldman Sachs
New York
+$8.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.51M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$6.48M
5
Renaissance Technologies
Renaissance Technologies
New York
+$5.75M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$8.97M
2
PAM
Panagora Asset Management
Massachusetts
-$4.75M
3
SFM
Sphera Funds Management
Israel
-$4.51M
4
Two Sigma Investments
Two Sigma Investments
New York
-$4.28M
5
SCM
Scopia Capital Management
New York
-$4.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
126
Woodline Partners
California
– -$4M -281,423 Closed
SSA
127
Schonfeld Strategic Advisors
New York
– -$2.01M -141,489 Closed
OAM
128
Oxford Asset Management
United Kingdom
– -$1.47M -103,202 Closed
BIM
129
Bogle Investment Management
Massachusetts
– -$1.4M -98,796 Closed
SIM
130
Spark Investment Management
New York
– -$1.32M -92,800 Closed
ARTA
131
A.R.T. Advisors
New York
– -$1.03M -72,474 Closed
Rafferty Asset Management
132
Rafferty Asset Management
New York
– -$659K -46,425 Closed
Voloridge Investment Management
133
Voloridge Investment Management
Florida
– -$358K -25,178 Closed
Walleye Capital
134
Walleye Capital
New York
– -$269K -18,996 Closed
ECM
135
ExodusPoint Capital Management
New York
– -$267K -18,815 Closed
AC
136
Athanor Capital
New York
– -$259K -18,256 Closed
HF
137
HRT Financial
New York
– -$235K -16,595 Closed
ProShare Advisors
138
ProShare Advisors
Maryland
– -$212K -14,903 Closed
ACM
139
AlphaCrest Capital Management
New York
– -$200K -14,100 Closed
Walleye Trading
140
Walleye Trading
New York
– -$183K -12,909 Closed
DTL
141
Dynamic Technology Lab
Singapore
– -$176K -12,421 Closed
PCM
142
Palisade Capital Management
New Jersey
– -$163K -11,502 Closed
CANY
143
Caxton Associates (New York)
New York
– -$161K -11,346 Closed
AGM
144
Alpine Global Management
New York
– -$160K -11,234 Closed
Nomura Holdings
145
Nomura Holdings
Japan
– -$135K -9,503 Closed
MAM
146
Meeder Asset Management
Ohio
– -$23K -1,645 Closed
PCM
147
Prelude Capital Management
New York
– -$11K -800 Closed
Simplex Trading
148
Simplex Trading
Illinois
– -$1.99K -132 Closed
2 3 4 5
6

TVTX Hedge Fund Activity: Q1 2020 in Review

124 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2020, worth a combined $643M — up 5.2% from $611M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of TVTX and 20 opened new positions — a net loss of 6 holders — while 49 trimmed existing stakes and 32 added.

The largest buyer was Adage Capital Partners, adding an estimated $14.5M. The largest seller was Millennium Management, cutting an estimated $8.97M.

  • 124 institutional investors held Travere Therapeutics (TVTX) as of Q1 2020, down from 131 in Q4 2019.
  • Funds reported $643M of Travere Therapeutics stock for Q1 2020, up 5.2% quarter-over-quarter.
  • 20 funds opened new Travere Therapeutics positions in Q1 2020 and 26 closed out, a net change of -6 holders.
  • The largest Travere Therapeutics buyer in Q1 2020 was Adage Capital Partners, an estimated $14.5M added.
  • The largest Travere Therapeutics seller in Q1 2020 was Millennium Management, an estimated $8.97M sold.

Based on aggregated 13F filings for Q1 2020.